Friday , 12 July 2024

Design and Development of Modified Release Solid Oral Dosage Form (Tolcapone)

Dr. Hareesh Dara*, D. Siva Dinesh, Thatipelli Ravichander
St John College of Pharmcy, Hasanparthy, Hanamkonda, Telangana, India

The present research work focuses on design and development of modified Release solid oral dosage form. Tolcapone: based on the assessment of various parameters, in vitro drug dissolution profile and drug kinetics, hf16 was found to be optimized formulation. The drug release from hf16 was found to fit zero order and best fitted to higuchi’s model confirming to be the diffusion assisted mechanism. FT-IR & DSC studies revealed that there was no interaction between the drug and polymers used in the formulations. In vivo bioavailability studies were conducted for optimized tolcapone trilayer tablets and marketed product, in vivo studies indicating that the optimized tolcapone formulation was shown sustained release patterns where marketed product was shown immediate release. So the optimized formulation was shown significant plasma concentrations with sustained release and maintained for 24 h. Based on the mucoadhesive study, the optimized dosage form adhesive to gastro intestinal tract more than 12 hours.
Keywords: Tolcapone, FT-IR, DSC, mucoadhesive study

Scroll To Top